A Great New Year for Dividend Stocks
It sure has been a crazy year to say the least. Normally, I hate to see years pass because I don’t like getting older. But in this case I’ll make an exception. Good riddance 2020, and take pandemic...
Read More
Vaccine Euphoria
It’s another week and another vaccine rally for the market. For the third straight week, a company has announced positive trial results for a coronavirus vaccine. The market loves it every time. The major indexes are now at or very near all-time don’t...
Read More
A Perfect Stock for this Wacky Environment
This is a tricky market, to say the least.
It’s earnings season. Earnings are always a wild card, no matter what you think you know about a company. You never know what a company will report of what say,...
Read More
The Selloff Creates an Amazing Income Opportunity
The incredible rally from the March lows has been disrupted. After soaring a remarkable 60% from the March lows, the S&P has pulled back more than 8% from its early-September high. Where do we go from here?
Aside the...
Read More
Two Stocks for the Post-Pandemic World
It might be time to look past the pandemic. Do we dare?
I know it seems like it will never end. Who knows when there will be an effective vaccine available? It’s easy to get a sense that things stay...
Read More
Earn High Income from an Out-of-Favor Titan
This is a wild market environment, the likes of which I have never seen. A self-induced economic crash to defend against a pandemic is a new one on me, and everybody else. I strongly believe in the economy...
Read More
This healthcare ETF is also rated ‘Strong Buy’ by Zacks.
Read More
While small caps as a group lagged behind the broad market in 2017, these three small-cap sectors have plenty of momentum and are poised for more in 2018.
Read More
Stock indexes stumbled again yesterday, June 29, led by large-cap tech stocks. Thus far, the profit-taking looks normal. Technology stocks have been on a tear in 2017, so investors are taking advantage of sky-high prices to harvest extraordinary gains.
Read More
Based on new data and improved prospects, I have raised my Min Sell Price for Gilead Sciences to 79.79 from 71.83.
Read More
The heart of the Contrary Opinion Forum is the talks by some of the best independent thinkers in the investment business.
Read More
The healthcare column I wrote on Monday resulted in my heaviest email volume ever and I thank everyone who responded. In total, 69% of respondents were supportive, 6% were critical, and the remainder addressed other items in the column, mainly American International Group which...
Read More